Silexion Therapeutics
SLXN
3 hedge funds and large institutions have $613K invested in Silexion Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.49% more ownership
Funds ownership: 0% → 1.49% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wildcat Capital Management
New York
|
+$1.21M |
| 2 |
HRT Financial
New York
|
+$113K |
| 3 |
Virtu Financial
New York
|
+$37.7K |
Top Sellers
SLXN Hedge Fund Activity: Q3 2024 in Review
3 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2024, worth a combined $613K.
Buyers outnumbered sellers: 3 funds opened new SLXN positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wildcat Capital Management, opening a new position worth an estimated $1.21M.
- 3 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2024, up from 0 in Q2 2024.
- Funds reported $613K of Silexion Therapeutics stock for Q3 2024.
- 3 funds opened new Silexion Therapeutics positions in Q3 2024 and 0 closed out, a net change of +3 holders.
- The largest Silexion Therapeutics buyer in Q3 2024 was Wildcat Capital Management, an estimated $1.21M added.
Based on aggregated 13F filings for Q3 2024.